Endotypic Trait Responses to 12-Month Tirzepatide Treatment for an Obese Patient with Obstructive Sleep Apnea: A Case Report

In a 35-year-old obese man with severe obstructive sleep apnea, 12 months of tirzepatide treatment reduced body mass index from 31.0 to 24.9 kg/m2 and the apnea-hypopnea index from 54.8 to 4.4 events/h, with favorable changes in endotypic traits. The authors suggest tirzepatide may improve OSA through both weight loss and altered airway physiology and ventilatory control.

Case report — Single-patient case report. Population: A 35-year-old obese man with severe obstructive sleep apnea. Sample size: 1 patient. Follow-up: 12 months. Interventions: Tirzepatide.

A 35-year-old man with severe OSA was treated with tirzepatide for 12 months. His BMI decreased from 31.0 to 24.9 kg/m2 and his AHI decreased from 54.8 to 4.4 events/h. Endotypic traits showed improved upper airway patency, increased compensatory pharyngeal muscle responsiveness, reduced loop gain, and a lower arousal threshold. Event duration was paradoxically longer.

For researchers studying tirzepatide, this case adds mechanistic detail by linking tirzepatide-associated OSA improvement to specific endotypic traits, not just AHI and BMI reductions. It does not establish efficacy, dose-response, or a generalizable treatment effect because it is an uncontrolled single case.

Key findings

• After 12 months of tirzepatide, the patient's BMI decreased from 31.0 to 24.9 kg/m2.
• The apnea-hypopnea index fell from 54.8 to 4.4 events/h over the same period.
• Endotypic testing indicated improved upper airway patency.
• Compensatory pharyngeal muscle responsiveness increased and loop gain was reduced.
• The arousal threshold was lower, while event duration was paradoxically longer.

Limitations

• Single-case design limits generalizability
• No control or comparator arm
• Cannot determine whether improvements were due directly to tirzepatide, weight loss, or both
• No follow-up beyond the 12-month treatment period

The record

• Journal: Obesity facts: 1-4
• Published: 2026-06-30
• PMID: 42378200 — DOI: 10.1159/000553125
• Author countries: Iceland, Taiwan

Peptide profiles: Tirzepatide.

All indexed evidence: Tirzepatide trials & papers.

Related studies: Peripheral nerve complications from medications utilised for weight loss: a systematic…, Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of…, Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory…, Comparative effects of drugs for adults with overweight or obesity: systematic review….